 |
 |
 |
 |
 |
 |
 |
 |
 |
| Altapure HJ600
The Altapure HJ600 not only engages and eliminates Healthcare Associated MRSA but affords an opportunity to engage and eliminate Community Associated MRSA. These pathogens and infections are emerging, vibrant, growing in strength and are a major expense and concern to Hospitals and the general public. Altapure is the answer to these concerns. "I was very impressed by the results of our initial challenge experiments in a test chamber last summer undertaken to evaluate the ALTAPURE technology in a simulated healthcare setting. The results confirmed that a brief exposure to the dilute peracetic acid-hydrogen peroxide aerosol totally sterilized a wide variety of solid surfaces as well as fabrics heavily monocontaminated by clinical isolates of methicillin-resistant Staph aureus (MRSA), vancomycin-resistant Enterococcus (VRE), Pseudomonas aeruginosa, Acinetobacter baumannii and, especially, the spores of Clostridium difficile." Click here to read Dr. Maki's letter "It may seem a strange principle to enunciate as the very first requirement in a hospital that it should do the sick no harm." |
 |
Facts About HAIs
Nosocomial, or hospital-acquired, infections remain a major challenge in United States healthcare institutions. Despite advances in antibiotic, disinfection agents and processes, many experts believe that we are losing this war. Infections contracted in hospitals represent the fourth largest killer in America. Current estimates suggest two million patients will contract infections while in hospitals and an estimated 103,000 will die as a result. This represents as many deaths as from AIDS, breast cancer and auto accidents combined.
- More than 2 million patients each year contract a Hospital Acquired Infection.
- Over 100,000 hospital patients die each year from HAIs. (greater than the deaths from motor vehicle accidents, breast cancer and AIDs combined)
- MRSA can survive on dry environmental surfaces for longer than 8 months and C-Diff can exist for more than 5 months.
- The U.S. Center for Disease Control estimates the treatment cost of HAIs is between $28-33 billion annually.
- Medicare regulations changed October 1, 2008 declare the cost of HAIs as no longer covered. Private insurers are also adopting this change in coverage.
- Soon all states will require hospitals to publish infection rates.
 |
 |
|||||||
|
